posted on 2018-08-21, 00:00authored byManjuan Liu, Aurélie Mallinger, Marcello Tortorici, Yvette Newbatt, Meirion Richards, Amin Mirza, Rob L. M. van Montfort, Rosemary Burke, Julian Blagg, Teresa Kaserer
APOBEC3B
(A3B) deamination activity on ssDNA is considered a contributing
factor to tumor heterogeneity and drug resistance in a number of human
cancers. Despite its clinical impact, little is known about A3B ssDNA
substrate preference. We have used nuclear magnetic resonance to monitor
the catalytic turnover of A3B substrates in real-time. This study
reports preferred nucleotide sequences for A3B substrates, including
optimized 4-mer oligonucleotides, and reveals a breadth of substrate
recognition that includes DNA sequences known to be mutated in drug-resistant
cancer clones. Our results are consistent with available clinical
and structural data and may inform the design of substrate-based A3B
inhibitors.